is the leading cause of death in the US, and
plays a major role in the development of heart disease. Cholesterol can be controlled with
statin drugs, a common treatment for many people.
You may think of cholesterol as just a number, but using statins has other benefits to your cardiovascular system. Research has shown that statins may reduce the incidence of
stroke, and death in people without cardiovascular disease. In fact, statins have a primary role in cardiovascular disease prevention.
Like most medications, statins have a good and bad side. In most cases, the benefits outweigh the risks. Here is some information about statins that will make you think beyond your cholesterol number.
Statins have been used primarily to treat high cholesterol. High levels of low-density lipoproteins (LDL, the bad cholesterol) combined with low levels of high-density lipoproteins (HDL, the good cholesterol) can lead to a condition called
atherosclerosis. Atherolsclerosis is a hardening of the arteries due to a build up of plaque on the inner walls. It is a condition that can lead to a
Statin drugs, like atorvastatin, pravastatin, and simvastatin, work by inhibiting a liver enzyme that is involved in the production of cholesterol. They are most effective at lowering levels of LDL cholesterol and may also contribute to increasing levels of HDL cholesterol.
Statins have become a popular choice to treat cholesterol problems because they are effective and generally well-tolerated.
Researchers have investigated the potential health benefits of taking statins. There is evidence that statins may reduce the risk of:
Statins may also help lower blood pressure.
If your doctor prescribes statins, some common side effects that you may have include:
Serious possible side effects include:
As with any medication there may also be a risk of an interaction with other medications.
If you have cholesterol problems, have coronary artery disease, or are at risk for coronary artery disease, your doctor will weight the benefits and risk of taking medications like statins. Be sure to discuss your medical history and any concerns that you may have about taking this kind of medicine. Keep in mind, too, that a healthy cardiovascular system depends on more than just taking statins. Your doctor will most likely recommend that you make lifestyle changes that include eating a healthier diet and exercising more.
American Heart Association
National Heart, Lung, and Blood Institute
Heart and Stroke Foundation of Canada
Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Coronary artery disease (CAD). EBSCO DynaMed website. Available at:
http://www.ebscohost.com/dynamed. Updated January 13, 2015. Accessed March 26, 2015.
Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria.
Ann Intern Med.
Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study.
Int J Cancer.
Graaf MR, Beiderbeck AB, Egberts AC, et al. The risk of cancer in users of statins.
J Clin Oncol.
Ichihara A, Hayashi M, Ryuzaki M, et al. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus.
Nephrol Dial Transplant.
Jick H, Zomberg GL, Jick SS, et al. Statins and the risk of dementia.
Kshirsagar AV, Shoham DA, Bang H, et al. The effect of cholesterol reduction with cholestyramine on renal function.
Am J Kidney Dis.
Statins. EBSCO DynaMed website. Available at:
http://www.ebscohost.com/dynamed. Updated March 4, 2015. Accessed March 26, 2015.
Statins and cancer risk. EBSCO DynaMed website. Available at:
http://www.ebscohost.com/dynamed. Updated June 13, 2014. Accessed March 26, 2015.
Statins for prevention of cardiovascular disease. EBSCO DynaMed website. Available at:
http://www.ebscohost.com/dynamed. Updated December 18, 2014. Accessed March 26, 2015.
Wolozin B, Kellman W, Rousseau P, et al. Decreased prevalence of Alzheimer's disease
associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
1/30/2009 DynaMed's Systematic Literature Surveillance
http://www.ebscohost.com/dynamed: Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
J Am Coll Cardiol.
3/6/2012 DynaMed's Systematic Literature Surveillance
http://www.ebscohost.com/dynamed: FDA announces safety changes in labeling for some cholesterol-lowering drugs. US Food and Drug Administration website. Available at:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm293623.htm. Published February 28, 2012. Accessed March 26, 2015.
Last reviewed March 2015 by Michael Woods, MD
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.